Clinical Trials | June 04, 2024
Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Sales reflect continued strong growth in oncology and vaccines
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
